Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)
China · Delayed Price · Currency is CNY 47.76
+1.84 (4.01%)
At close: Feb 6, 2026
SHA:600329 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,351 | 7,292 | 8,206 | 8,231 | 6,892 | 6,590 |
Other Revenue | 14.25 | 14.25 | 16.23 | 17.87 | 15.33 | 13.64 |
| 5,366 | 7,307 | 8,222 | 8,249 | 6,908 | 6,604 | |
Revenue Growth (YoY) | -33.27% | -11.13% | -0.33% | 19.42% | 4.60% | -5.58% |
Cost of Revenue | 1,858 | 3,804 | 4,632 | 4,992 | 4,161 | 4,024 |
Gross Profit | 3,507 | 3,503 | 3,590 | 3,258 | 2,747 | 2,580 |
Selling, General & Admin | 2,360 | 2,459 | 2,508 | 2,347 | 1,930 | 1,815 |
Research & Development | 168.2 | 162.38 | 184.63 | 153.15 | 161.05 | 149.2 |
Other Operating Expenses | 67.45 | 63.44 | 57.28 | 76.69 | 64.12 | 58.29 |
Operating Expenses | 2,620 | 2,729 | 2,769 | 2,586 | 2,160 | 2,029 |
Operating Income | 886.95 | 774.04 | 821.03 | 671.32 | 587.04 | 551.04 |
Interest Expense | -17.41 | -40.2 | -35.85 | -10.27 | -2.94 | -0.01 |
Interest & Investment Income | 3,398 | 1,937 | 362.75 | 330.35 | 263.97 | 188.48 |
Currency Exchange Gain (Loss) | -1.51 | -1.51 | -1.13 | -2.44 | 0.69 | 1.73 |
Other Non Operating Income (Expenses) | -8.04 | -2.55 | -2.71 | 3.63 | -5.3 | -6.27 |
EBT Excluding Unusual Items | 4,258 | 2,666 | 1,144 | 992.59 | 843.46 | 734.98 |
Impairment of Goodwill | -53.61 | -53.61 | -18.78 | -19.57 | - | - |
Gain (Loss) on Sale of Assets | 3.66 | 0.07 | -0.48 | 0.67 | 10.39 | 6.62 |
Asset Writedown | -58.22 | -60.16 | -24.95 | -0.18 | - | - |
Other Unusual Items | 26.13 | 26.13 | -4.51 | 6.67 | 18.96 | 26.46 |
Pretax Income | 4,176 | 2,579 | 1,095 | 980.19 | 872.81 | 768.06 |
Income Tax Expense | 607.28 | 363.56 | 126.66 | 106.93 | 85.93 | 88.4 |
Earnings From Continuing Operations | 3,568 | 2,215 | 968.71 | 873.26 | 786.88 | 679.66 |
Minority Interest in Earnings | 9.36 | 14.12 | 18 | -11.46 | -17.73 | -17.96 |
Net Income | 3,578 | 2,229 | 986.71 | 861.79 | 769.14 | 661.7 |
Net Income to Common | 3,578 | 2,229 | 986.71 | 861.79 | 769.14 | 661.7 |
Net Income Growth | 283.72% | 125.94% | 14.49% | 12.05% | 16.24% | 5.78% |
Shares Outstanding (Basic) | 766 | 769 | 771 | 769 | 769 | 769 |
Shares Outstanding (Diluted) | 768 | 771 | 771 | 776 | 769 | 769 |
Shares Change (YoY) | -0.33% | 0.07% | -0.71% | 0.94% | -0.04% | -0.37% |
EPS (Basic) | 4.67 | 2.90 | 1.28 | 1.12 | 1.00 | 0.86 |
EPS (Diluted) | 4.66 | 2.89 | 1.28 | 1.11 | 1.00 | 0.86 |
EPS Growth | 284.99% | 125.78% | 15.32% | 11.00% | 16.28% | 6.17% |
Free Cash Flow | 846.48 | 806.86 | 547.56 | 569.34 | 695.45 | 482.26 |
Free Cash Flow Per Share | 1.10 | 1.05 | 0.71 | 0.73 | 0.90 | 0.63 |
Dividend Per Share | 1.280 | 1.280 | 1.280 | 1.120 | 0.500 | 0.300 |
Dividend Growth | - | - | 14.29% | 124.00% | 66.67% | - |
Gross Margin | 65.37% | 47.94% | 43.66% | 39.49% | 39.77% | 39.07% |
Operating Margin | 16.53% | 10.59% | 9.98% | 8.14% | 8.50% | 8.34% |
Profit Margin | 66.68% | 30.51% | 12.00% | 10.45% | 11.13% | 10.02% |
Free Cash Flow Margin | 15.78% | 11.04% | 6.66% | 6.90% | 10.07% | 7.30% |
EBITDA | 1,000 | 893.19 | 947.65 | 786.15 | 701.29 | 660.9 |
EBITDA Margin | 18.65% | 12.22% | 11.53% | 9.53% | 10.15% | 10.01% |
D&A For EBITDA | 113.54 | 119.15 | 126.62 | 114.83 | 114.25 | 109.85 |
EBIT | 886.95 | 774.04 | 821.03 | 671.32 | 587.04 | 551.04 |
EBIT Margin | 16.53% | 10.59% | 9.98% | 8.14% | 8.50% | 8.34% |
Effective Tax Rate | 14.54% | 14.10% | 11.56% | 10.91% | 9.84% | 11.51% |
Revenue as Reported | 5,366 | 7,307 | 8,222 | 8,249 | 6,908 | 6,604 |
Advertising Expenses | - | 445.36 | 437.2 | - | 321.16 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.